Zacks Investment Research lowered shares of ORION OYJ/ADR (OTCMKTS:ORINY) from a buy rating to a hold rating in a report published on Thursday.

According to Zacks, “Orion Oyj is a pharmaceutical company. It develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company’s core therapy consists of central nervous system disorders, oncology and respiratory. Its product pipeline includes inhaled Easyhaler(R) pulmonary drugs. Orion Oyj is headquartered in Espoo, Finland. “

OTCMKTS ORINY opened at $18.20 on Thursday. The company has a market cap of $5.15 billion, a P/E ratio of 20.00 and a beta of 0.51. ORION OYJ/ADR has a one year low of $15.00 and a one year high of $21.17.


Orion Oyj engages in the development and manufacture of pharmaceuticals, active pharmaceutical ingredients (APIs), and diagnostic tests worldwide. The company operates in two segments, Pharmaceuticals and Diagnostics. The Pharmaceuticals segment develops, manufactures, and markets pharmaceuticals and APIs.

See Also: Technical Analysis of Stocks, How Can It Help

Get a free copy of the Zacks research report on ORION OYJ/ADR (ORINY)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for ORION OYJ/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ORION OYJ/ADR and related companies with's FREE daily email newsletter.